Kadoaki Ohashi

List of Publications by Citations

105 papers	3,586 citations	20 h-index	59 g-index
132 ext. papers	4,391 ext. citations	5.4 avg, IF	4.66 L-index

#	Paper	IF	Citations
105	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. *Cancer Discovery*, **2012**, 2, 922-33	24.4	528
104	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. *Cancer Discovery*, **2013**, 3, 1404-15	24.4	493
103	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. *Science Translational Medicine*, **2011**, 3, 90ra59	17.5	383
102	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E2127-33	11.5	366
101	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. *Journal of Clinical Oncology*, **2013**, 31, 1070-80	2.2	362
100	Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2020**, 383, 944-957	59.2	214
99	Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2020**, 383, 813-824	59.2	194
98	Characteristics of lung cancers harboring NRAS mutations. *Clinical Cancer Research*, **2013**, 19, 2584-91	12.9	100
97	Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. *Cancer Research*, **2016**, 76, 1506-16	10.1	91
96	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 273-279	8.9	74
95	Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. *Lung Cancer*, **2006**, 53, 117-21	5.9	53
94	Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. *Cancer Research*, **2009**, 69, 5091-8	10.1	52
93	Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. *Genome Research*, **2013**, 23, 1434-45	9.7	41
92	JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. *Cancer Science*, **2012**, 103, 1795-802	6.9	38
91	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. *Japanese Journal of Clinical Oncology*, **2019**, 49, 762-765	2.8	30
90	NF-B drives acquired resistance to a novel mutant-selective EGFR inhibitor. *Oncotarget*, **2015**, 6, 42717-33	3.3	27
89	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. *Scientific Reports*, **2018**, 8, 1955	4.9	26

88	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. *Oncotarget*, **2018**, 9, 29525-29531	3.3	25
87	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model. *Cancer Science*, **2013**, 104, 1440-6	6.9	24
86	Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. *Experimental Cell Research*, **2013**, 319, 417-23	4.2	20
85	Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. *Clinical Lung Cancer*, **2017**, 18, 92-95	4.9	19
84	Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. *Cancer Science*, **2008**, 99, 1747-53	6.9	19
83	A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. *Lung Cancer*, **2018**, 115, 103-108	5.9	19
82	A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY). *Chest*, **2019**, 156, 357-366	5.3	16
81	STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. *Lung Cancer*, **2012**, 75, 24-9	5.9	16
80	Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. *Cancer Research*, **2009**, 69, 7088-95	10.1	16
79	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. *Acta Oncologica*, **2020**, 59, 249-256	3.2	15
78	Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. *PLoS ONE*, **2015**, 10, e0121211	3.7	14
77	Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. *Biochemical and Biophysical Research Communications*, **2018**, 495, 360-367	3.4	14
76	Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study. *Cancer Medicine*, **2020**, 9, 6597-6608	4.8	13
75	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. *Journal of Thoracic Oncology*, **2019**, 14, 2009-2018	8.9	12
74	The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer.. *Journal of Clinical Oncology*, **2017**, 35, e20601-e20601	2.2	12
73	Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. *Cancer Science*, **2018**, 109, 3149-3158	6.9	12
72	Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system. *Oncology Reports*, **2017**, 37, 3100-3106	3.5	11
71	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). *Clinical Lung Cancer*, **2016**, 17, 602-605	4.9	10

70	Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model. *Cancer Science*, **2015**, 106, 1296-302	6.9	10
69	A new target for therapy in squamous cell carcinoma of the lung. *Cancer Discovery*, **2011**, 1, 23-4	24.4	10
68	Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo. *Molecular Oncology*, **2017**, 11, 670-681	7.9	9
67	Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. *Japanese Journal of Clinical Oncology*, **2019**, 49, 458-464	2.8	9
66	Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. *Lung Cancer*, **2019**, 132, 54-58	5.9	9
65	Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung cancer. *Respiratory Investigation*, **2015**, 53, 93-7	3.4	9
64	Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice. *Lung Cancer*, **2009**, 65, 284-9	5.9	9
63	Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.. *Journal of Clinical Oncology*, **2020**, 38, 9509-9509	2.2	9
62	Pilot evaluation of a HER2 testing in non-small-cell lung cancer. *Journal of Clinical Pathology*, **2020**, 73, 353-357	3.9	8
61	Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. *Japanese Journal of Clinical Oncology*, **2016**, 46, 871-4	2.8	7
60	Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. *Trials*, **2020**, 21, 298	2.8	6
59	Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistancein vitro. **2013**,		6
58	A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. *Internal Medicine*, **2019**, 58, 3033-3037	1.1	5
57	Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. *Experimental Cell Research*, **2014**, 326, 201-9	4.2	5
56	Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review. *Internal Medicine*, **2020**, 59, 823-828	1.1	5
55	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. *Japanese Journal of Clinical Oncology*, **2020**, 50, 1447-1453	2.8	5
54	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers. *Cancer Science*, **2021**, 112, 1853-1864	6.9	5
53	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. *Cancer Chemotherapy and Pharmacology*, **2016**, 78, 941-947	3.5	5

52	Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial. *Asia-Pacific Journal of Clinical Oncology*, **2021**, 17, 101-108	1.9	5
51	Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M. *Journal of Thoracic Oncology*, **2018**, 13, e140-e142	8.9	4
50	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. *Lung Cancer*, **2017**, 112, 188-194	5.9	4
49	Ruptured littoral cell angiosarcoma causing hemoperitoneum. *Internal Medicine*, **2012**, 51, 337-8	1.1	4
48	Contribution of nationwide genome screening in Japan (LC-SCRUM-Japan) to the development of precision medicine for non-small cell lung cancer.. *Journal of Clinical Oncology*, **2018**, 36, 9085-9085	2.2	4
47	Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS-mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).. *Journal of Clinical Oncology*, **2020**, 38, 9589-9589	2.2	4
46	Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. *OncoTargets and Therapy*, **2016**, 9, 1753-8	4.4	4
45	Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study. *Cancer Science*, **2021**, 112, 1556-1566	6.9	4
44	Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol. *Acta Medica Okayama*, **2018**, 72, 319-323	0.5	4
43	Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. *Japanese Journal of Clinical Oncology*, **2017**, 47, 434-437	2.8	3
42	Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. *Japanese Journal of Clinical Oncology*, **2018**, 48, 287-290	2.8	3
41	Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review. *Respiratory Medicine Case Reports*, **2019**, 28, 100938	1.2	3
40	Abstract 2131: Significant combination benefit of anti-VEGFR antibody and oncogene-targeted agents in EGFR or ALK mutant NSCLC cells **2019**,		3
39	Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). *Translational Lung Cancer Research*, **2021**, 10, 314-325	4.4	3
38	EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice. *Lung Cancer*, **2019**, 136, 86-93	5.9	2
37	Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. *Internal Medicine*, **2019**, 58, 1625-1627	1.1	2
36	Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. *Respiratory Investigation*, **2019**, 57, 460-465	3.4	2
35	A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. *Asia-Pacific Journal of Clinical Oncology*, **2019**, 15, 250-256	1.9	2

34	Radiation necrosis mimicking progressive brain metastasis in a patient with non-small cell lung cancer. *Journal of Thoracic Oncology*, **2007**, 2, 762-3	8.9	2
33	The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.. *Journal of Clinical Oncology*, **2018**, 36, e21147-e21147	2.2	2
32	Large scale clinico-genomic analyses among patients with BRAF-mutated non-small cell lung cancers (NSCLC) identified by nationwide genomic screening project (LC-SCRUM-Japan).. *Journal of Clinical Oncology*, **2020**, 38, 9590-9590	2.2	2
31	Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. *Biochemical and Biophysical Research Communications*, **2020**, 532, 341-346	3.4	2
30	Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. *Lung Cancer*, **2020**, 150, 83-89	5.9	2
29	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. *Japanese Journal of Clinical Oncology*, **2021**, 51, 956-965	2.8	2
28	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve , or -altered Non-small Cell Lung Cancer. *Molecular Cancer Therapeutics*, **2021**, 20, 1653-1662	6.1	2
27	Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. *Japanese Journal of Clinical Oncology*, **2021**, 51, 1269-1276	2.8	2
26	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. *Nature Communications*, **2021**, 12, 5505	17.4	2
25	Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. *Japanese Journal of Clinical Oncology*, **2016**, 46, 529-33	2.8	1
24	Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study.. *Lung Cancer*, **2021**, 165, 152-163	5.9	1
23	Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.. *Journal of Clinical Oncology*, **2019**, 37, 9056-9056	2.2	1
22	Randomized phase II study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in advanced non-small cell lung cancer: The OLCSG1406 trial.. *Journal of Clinical Oncology*, **2019**, 37, e23105-e23105	2.2	1
21	Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies. *Acta Medica Okayama*, **2020**, 74, 371-379	0.5	1
20	Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction. *Oncology Letters*, **2020**, 20, 393	2.6	1
19	A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1 lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations. *Lung Cancer*, **2021**, 156, 1-4	5.9	1
18	Identification of targetable kinases in idiopathic pulmonary fibrosis.. *Respiratory Research*, **2022**, 23, 20	7.3	0
17	PatientsTpreferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. *Acta Oncologica*, **2020**, 59, 324-328	3.2	0

16	Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. *Respiratory Investigation*, **2021**, 59, 240-246	3.4	0
15	A case of axillary lymphadenitis caused by in an immunocompetent patient. *Respiratory Medicine Case Reports*, **2019**, 28, 100947	1.2	
14	Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.. *Journal of Clinical Oncology*, **2018**, 36, e21034-e21034	2.2	
13	Tumor microenvironment affecting the effect of immuno-checkpoint inhibitors. *Okayama Igakkai Zasshi*, **2019**, 131, 51-53	0	
12	Time trend in the survival advantage in phase III trials investigating molecular-targeted agents for advanced non-small cell lung cancer (NSCLC) during the past decade.. *Journal of Clinical Oncology*, **2014**, 32, e19084-e19084	2.2	
11	A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy.	0	
10	Development of a nationwide genomic screening network for squamous cell lung cancer in Japan (LC-SCRUM-Japan).. *Journal of Clinical Oncology*, **2016**, 34, 9097-9097	2.2	
9	Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery.. *Journal of Clinical Oncology*, **2016**, 34, 10100-10100	2.2	
8	Association with consolidation chemotherapy after concurrent chemoradiotherapyfollowed by surgery and the disease free survival in patients with stage III non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2016**, 34, e20053-e20053	2.2	
7	Development of nationwide genomic screening project (LC-SCRUM-Japan) contributing to the establishment of precision medicine in Japan.. *Journal of Clinical Oncology*, **2016**, 34, 9089-9089	2.2	
6	Chemoradiotherapy (CRT) for locally-advanced (LA) lung cancer patients with interstitial lung abnormalities (ILA).. *Journal of Clinical Oncology*, **2017**, 35, e20057-e20057	2.2	
5	Contribution to the development of precision medicine and clinical utility of nationwide lung cancer genomic screening in Japan (LC-SCRUM-Japan).. *Journal of Clinical Oncology*, **2017**, 35, e20659-e20659	2.2	
4	Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.. *Journal of Clinical Oncology*, **2021**, 39, 9040-9040	2.2	
3	Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.. *Journal of Clinical Oncology*, **2021**, 39, e20590-e20590	2.2	
2	Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1TGF- expression. *Oncology Letters*, **2021**, 22, 639	2.6	
1	Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation. *Acta Medica Okayama*, **2016**, 70, 243-53	0.5	